Global Myelofibrosis Treatment Market to Grow at 4.56% During 2024-2032, Propelled by Increasing Incidences of Genetic Abnormalities

September 29, 2022 | Healthcare

According to the latest report by IMARC Group, titled “Myelofibrosis Treatment Market Report by Drug Type (Hydroxyurea, Immunomodulators, JAK Inhibitor, and Others), Treatment Type (Blood Transfusion, Chemotherapy, Androgen Therapy, Stem Cell/Bone Marrow Transplantation, and Others), End User (Hospitals and Clinics, Bone Marrow Transplant Centres, and Others), and Region 2024-2032”, the global myelofibrosis treatment market is expected to exhibit a growth rate (CAGR) of 4.56% during 2024-2032. Myelofibrosis is a myeloproliferative condition characterized by the proliferation of defective hematopoietic stem cell clones that compromises the bone marrow's ability to make blood. Several tests are available to diagnose this disease, including physical examinations, blood tests, bone marrow tests, imaging tests, and human leukocyte antigen (HLA) typing. Most of these treatment options for myelofibrosis focus on preventing blood count problems and splenomegaly. Furthermore, several drugs are being introduced in the market that provide relief from symptoms of the disease as well as reduce blood volume.

Global Myelofibrosis Treatment Market Trends:

The global market is primarily driven by the increasing incidences of genetic abnormalities and blood disorders, such as thrombocythemia and polycythemia vera. This can be attributed to poor lifestyle choices of the masses as well as prolonged exposure to industrial chemicals and high levels of radiation. In addition to this, the expanding geriatric population that is susceptible to developing numerous chronic illnesses is resulting in an increased demand for myelofibrosis treatment. Moreover, the introduction of novel drugs for relieving chronic symptoms of myelofibrotic patients is providing an impetus to the market. The market is further driven by the significant investments made by the major pharmaceutical companies for extensive research and development (R&D) activities. Apart from this, favorable government initiatives and improved reimbursement policies for myelofibrosis treatment are creating a positive market outlook. Some of the other factors contributing to the market include continual improvements in healthcare infrastructure, easy availability of chemotherapeutic drugs via online and offline organized retail channels and inflating disposable income levels.

Market Summary:

Based on the drug type, the market has been segmented into hydroxyurea, immunomodulators, JAK inhibitor, and others.
On the basis of the treatment type, the market has been divided into blood transfusion, chemotherapy, androgen therapy, stem cell/bone marrow transplantation, and others.
Based on the end user, the market has been categorized into hospitals and clinics, bone marrow transplant centres, and others.
On the geographical front, the market has been segregated into North America (the United States and Canada), Asia Pacific (China, Japan, India, South Korea, Australia, Indonesia and others), Europe (Germany, France, the United Kingdom, Italy, Spain, Russia and others), Latin America (Brazil, Mexico and others), and Middle East and Africa.
The competitive landscape of the market has been studied in the report with the detailed profiles of the key players. Some of these players include AllCells LLC, American Type Culture Collection Inc, Amgen Inc, Bristol-Myers Squibb Company, Eli Lilly and Company, F. Hoffmann-La Roche AG, Gilead Sciences Inc., Incyte Corporation, Merck & Co. Inc., and Novartis AG.

Report Scope:

Report Features	Details
Base Year of the Analysis	2023
Historical Period	2018-2023
Forecast Period	2024-2032
Units	US$ Million
Segment Coverage	Drug Type, Treatment Type, End User, Region
Region Covered	Asia Pacific, Europe, North America, Latin America, Middle East and Africa
Countries Covered	United States, Canada, Germany, France, United Kingdom, Italy, Spain, Russia, China, Japan, India, South Korea, Australia, Indonesia, Brazil, Mexico
Companies Covered	AllCells LLC, American Type Culture Collection Inc, Amgen Inc, Bristol-Myers Squibb Company, Eli Lilly and Company, F. Hoffmann-La Roche AG, Gilead Sciences Inc., Incyte Corporation, Merck & Co. Inc. and Novartis AG
Customization Scope	10% Free Customization
Report Price and Purchase Option	Single User License: US$ 3899 Five User License: US$ 4899 Corporate License: US$ 5899
Post-Sale Analyst Support	10-12 Weeks
Delivery Format	PDF and Excel through Email (We can also provide the editable version of the report in PPT/Word format on special request)

About Us:

IMARC Group is a leading market research company that offers management strategy and market research worldwide. We partner with clients in all sectors and regions to identify their highest-value opportunities, address their most critical challenges, and transform their businesses.

IMARC’s information products include major market, scientific, economic and technological developments for business leaders in pharmaceutical, industrial, and high technology organizations. Market forecasts and industry analysis for biotechnology, advanced materials, pharmaceuticals, food and beverage, travel and tourism, nanotechnology and novel processing methods are at the top of the company’s expertise.

Contact Us:

IMARC Group
30 N Gould St, Ste R
Sheridan, WY (Wyoming) 82801 USA
Email: Sales@imarcgroup.com
Tel No:(D) +91 120 433 0800
Americas:- +1 631 791 1145 | Africa and Europe :- +44-753-713-2163 | Asia: +91-120-433-0800

Need more help?

Speak to our experienced analysts for insights on the current market scenarios.
Include additional segments and countries to customize the report as per your requirement.
Gain an unparalleled competitive advantage in your domain by understanding how to utilize the report and positively impacting your operations and revenue.
For further assistance, please connect with our analysts.

Global Myelofibrosis Treatment Market to Grow at 4.56% During 2024-2032, Propelled by Increasing Incidences of Genetic Abnormalities

Purchase options

Single User License ~~$3899~~ $2999
Five User License ~~$4899~~ $3999
Corporate User License ~~$5899~~ $4999

Inquire Before Buying

Benefits of Customization

Personalize this research

Triangulate with your data

Get data as per your format and definition

Gain a deeper dive into a specific application, geography, customer, or competitor

Any level of personalization

Speak to an Analyst

Request Brochure

Get in Touch With Us

UNITED STATES

Phone: +1-631-791-1145

INDIA

Phone: +91-120-433-0800

UNITED KINGDOM

Phone: +44-753-713-2163

Email: sales@imarcgroup.com

Client Testimonials

IMARC made the whole process easy. Everyone I spoke with via email was polite, easy to deal with, kept their promises regarding delivery timelines and were solutions focused. From my first contact, I was grateful for the professionalism shown by the whole IMARC team. I recommend IMARC to all that need timely, affordable information and advice. My experience with IMARC was excellent and I can not fault it.

The IMARC team was very reactive and flexible with regard to our requests. A very good overall experience. We are happy with the work that IMARC has provided, very complete and detailed. It has contributed to our business needs and provided the market visibility that we required

We were very happy with the collaboration between IMARC and Colruyt. Not only were your prices competitive, IMARC was also pretty fast in understanding the scope and our needs for this project. Even though it was not an easy task, performing a market research during the COVID-19 pandemic, you were able to get us the necessary information we needed. The IMARC team was very easy to work with and they showed us that it would go the extra mile if we needed anything extra

Last project executed by your team was as per our expectations. We also would like to associate for more assignments this year. Kudos to your team.

We would be happy to reach out to IMARC again, if we need Market Research/Consulting/Consumer Research or any associated service. Overall experience was good, and the data points were quite helpful.

Arabian Plastic Manufacturing Company Ltd.

The figures of market study were very close to our assumed figures. The presentation of the study was neat and easy to analyse. The requested details of the study were fulfilled. My overall experience with the IMARC Team was satisfactory.

The overall cost of the services were within our expectations. I was happy to have good communications in a timely manner. It was a great and quick way to have the information I needed.

My questions and concerns were answered in a satisfied way. The costs of the services were within our expectations. My overall experience with the IMARC Team was very good.

I agree the report was timely delivered, meeting the key objectives of the engagement. We had some discussion on the contents, adjustments were made fast and accurate. The response time was minimum in each case. Very good. You have a satisfied customer.

We would be happy to reach out to IMARC for more market reports in the future. The response from the account sales manager was very good. I appreciate the timely follow ups and post purchase support from the team. My overall experience with IMARC was good.

IMARC was a good solution for the data points that we really needed and couldn't find elsewhere. The team was easy to work, quick to respond, and flexible to our customization requests.